[1] |
|
[2] |
CHUGH S S, HAVMOELLER R, NARAYANAN K,et al. Worldwide epidemiology of atrial fibrillation:a global burden of disease 2010 study[J]. Circulation, 2014, 129(8):837-847. DOI: 10.1161/CIRCULATIONAHA.113.005119.
|
[3] |
MORIN D P, BERNARD M L, MADIAS C,et al. The state of the art:atrial fibrillation epidemiology,prevention,and treatment[J]. Mayo Clin Proc, 2016, 91(12):1778-1810. DOI: 10.1016/j.mayocp.2016.08.022.
|
[4] |
STAERK L, SHERER J A, KO D,et al. Atrial fibrillation:epidemiology,pathophysiology,and clinical outcomes[J]. Circ Res, 2017, 120(9):1501-1517. DOI: 10.1161/CIRCRESAHA.117.309732.
|
[5] |
|
[6] |
|
[7] |
|
[8] |
KIRCHHOF P, BENUSSI S, KOTECHA D,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J]. Eur Heart J, 2016, 37(38):2893-2962. DOI: 10.1093/eurheartj/ehw210.
|
[9] |
PISTERS R, LANE D A, NIEUWLAAT R,et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation:the Euro Heart Survey[J]. Chest, 2010, 138(5):1093-1100. DOI: 10.1378/chest.10-0134.
|
[10] |
|
[11] |
AHO K,HARMSEN P,HATANO S,et al. Cerebrovascular disease in the community:results of a WHO collaborative study[J]. Bull World Health Organ,1980,58(1):113-130.
|
[12] |
|
[13] |
|
[14] |
KRAHN A D, MANFREDA J, TATER B,et al. The natural history of atrial fibrillation:incidence,risk factors,and prognosis in the Manitoba Follow-Up Study[J]. Am J Med, 1995, 98(5):476-484. DOI: 10.1016/S0002-9343(99)80348-9.
|
[15] |
CHAMBERLAIN A M, GERSH B J, ALONSO A,et al. No decline in the risk of heart failure after incident atrial fibrillation:a community study assessing trends overall and by ejection fraction[J]. Heart Rhythm, 2017, 14(6):791-798. DOI: 10.1016/j.hrthm.2017.01.031.
|
[16] |
|
[17] |
WOLFSON A M, FONG M, GRAZETTE L,et al. Chronic heart failure management and remote haemodynamic monitoring[J]. Heart, 2018, 104(23):1910-1919. DOI: 10.1136/heartjnl-2018-313397.
|
[18] |
WATTIGNEY W A, MENSAH G A, CROFT J B. Increasing trends in hospitalization for atrial fibrillation in the United States,1985 through 1999:implications for primary prevention[J]. Circulation, 2003, 108(6):711-716. DOI: 10.1161/01.CIR.0000083722.42033.0A.
|
[19] |
FRIBERG L, ROSENQVIST M, LINDGREN A,et al. High prevalence of atrial fibrillation among patients with ischemic stroke[J]. Stroke, 2014, 45(9):2599-2605. DOI: 10.1161/STROKEAHA.114.006070.
|
[20] |
FILIPPATOS G, FARMAKIS D. A look back:the quest for thrombosis in heart failure continues after COMMANDER HF[J]. Cardiovasc Res, 2019, 115(13):e140-142. DOI: 10.1093/cvr/cvz241.
|
[21] |
SILLER-MATULA J M, PECEN L, PATTI G,et al. Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation:the PREFER in AF - HF substudy[J]. Int J Cardiol, 2018, 265:141-147. DOI: 10.1016/j.ijcard.2018.04.093.
|
[22] |
GORST-RASMUSSEN A, SKJOTH F, LARSEN T B,et al. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis:a nationwide cohort study[J]. J Thromb Haemost, 2015, 13(4):495-504. DOI: 10.1111/jth.12845.
|
[23] |
MAZUREK M, HUISMAN M V, LIP G Y H. Registries in atrial fibrillation:from trials to real-life clinical practice[J]. Am J Med, 2017, 130(2):135-145. DOI: 10.1016/j.amjmed.2016.09.012.
|
[24] |
ZHENG H J, OUYANG S K, ZHAO Y,et al. The use status of anticoagulation drugs for inpatients with nonvalvular atrial fibrillation in Southwest China[J]. Int J Gen Med, 2017, 10:69-77. DOI: 10.2147/IJGM.S128047.
|
[25] |
|
[26] |
JANUARY C T, WANN L S, CALKINS H,et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation:areport of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society[J]. J Am Coll Cardiol, 2019, 74(1):104-132. DOI: 10.1016/j.jacc.2019.01.011.
|
[27] |
GIUGLIANO R P, RUFF C T, BRAUNWALD E,et al. Edoxaban versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2013, 369(22):2093-2104. DOI: 10.1056/NEJMoa1310907.
|
[28] |
YUZAWA H, INOUE H, YAMASHITA T,et al. Rhythm versus rate control strategies regarding anticoagulant use in elderly non-valvular atrial fibrillation patients:Subanalysis of the ANAFIE (All Nippon AF in the Elderly) Registry[J]. J Cardiol, 2020, 76(1):87-93. DOI: 10.1016/j.jjcc.2020.01.010.
|
[29] |
EIKELBOOM J W, CONNOLLY S J, BRUECKMANN M,et al. Dabigatran versus warfarin in patients with mechanical heart valves[J]. N Engl J Med, 2013, 369(13):1206-1214. DOI: 10.1056/NEJMoa1300615.
|
[30] |
BAIY, GUO S D, DENG H,et al. Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation:a systematic review and meta-regression analysis[J]. Age Ageing, 2018, 47(1):9-17. DOI: 10.1093/ageing/afx103.
|
[31] |
MAN-SON-HING M, NICHOL G, LAU A,et al. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls[J]. Arch Intern Med, 1999, 159(7):677-685. DOI: 10.1001/archinte.159.7.677.
|
[32] |
JANUARY C T, WANN L S, ALPERT J S,et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation:executive summary:a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society[J]. Circulation, 2014, 130(23):2071-2104. DOI: 10.1161/cir.0000000000000040.
|
[33] |
MELKONIAN M, JARZEBOWSKI W, PAUTAS E,et al. Bleeding risk of antiplatelet drugs compared with oral anticoagulants in older patients with atrial fibrillation:a systematic review and meta-analysis[J]. J Thromb Haemost, 2017, 15(7):1500-1510. DOI: 10.1111/jth.13697.
|
[34] |
PONIKOWSKI P, VOORS A A, ANKER S D,et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC[J]. Eur J Heart Fail, 2016, 18(8):891-975. DOI: 10.1002/ejhf.592.
|
[35] |
WILTON S B, LEUNG A A, GHALI W A,et al. Outcomes of cardiac resynchronization therapy in patients with versus those without atrial fibrillation:a systematic review and meta-analysis[J]. Heart Rhythm, 2011, 8(7):1088-1094. DOI: 10.1016/j.hrthm.2011.02.014.
|
[36] |
SAKATA Y, SHIMOKAWA H. Epidemiology of heart failure in Asia[J]. Circ J, 2013, 77(9):2209-2217. DOI: 10.1253/circj.cj-13-0971.
|
[37] |
BIASE L D, MOHANTY P, MOHANTY S,et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device:results from the AATAC multicenter randomized trial[J]. Circulation, 2016, 133(17):1637-1644. DOI: 10.1161/CIRCULATIONAHA.115.019406.
|
[38] |
|
[39] |
CONTRERAS J P, HONG K N, CASTILLO J,et al. Anticoagulation in patients with atrial fibrillation and heart failure:insights from the NCDR PINNACLE-AF registry[J]. Clin Cardiol, 2019, 42(3):339-345. DOI: 10.1002/clc.23142.
|